SubHero Banner

Keytruda® (pembrolizumab) – New indication

May 23, 2017 – The FDA announced the approval of Merck’s Keytruda (pembrolizumab) for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, or colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and Camptosar® (irinotecan).

Download PDF